Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI.

Treaba CA, Granberg TE, Sormani MP, Herranz E, Ouellette RA, Louapre C, Sloane JA, Kinkel RP, Mainero C.

Radiology. 2019 Jun;291(3):740-749. doi: 10.1148/radiol.2019181719. Epub 2019 Apr 9.

2.

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S.

Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809. doi: 10.1177/1756286419837809. eCollection 2019.

3.

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Minden SL, Kinkel RP, Machado HT, Levin JS, Rosenthal MB, Iezzoni LI.

Mult Scler J Exp Transl Clin. 2019 Feb 20;5(1):2055217318820888. doi: 10.1177/2055217318820888. eCollection 2019 Jan-Mar.

4.

Guided Imagery Improves Mood, Fatigue, and Quality of Life in Individuals With Multiple Sclerosis: An Exploratory Efficacy Trial of Healing Light Guided Imagery.

Case LK, Jackson P, Kinkel R, Mills PJ.

J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X17748744. doi: 10.1177/2515690X17748744.

5.

Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.

Louapre C, Govindarajan ST, Giannì C, Madigan N, Sloane JA, Treaba CA, Herranz E, Kinkel RP, Mainero C.

Mult Scler. 2018 Oct;24(11):1433-1444. doi: 10.1177/1352458517726382. Epub 2017 Aug 14.

PMID:
28803512
6.

The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI.

Louapre C, Govindarajan ST, Giannì C, Madigan N, Nielsen AS, Sloane JA, Kinkel RP, Mainero C.

Neuroimage Clin. 2016 Nov 3;12:879-886. eCollection 2016.

7.

Neuroinflammatory component of gray matter pathology in multiple sclerosis.

Herranz E, Giannì C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, Loggia ML, Sloane JA, Madigan N, Izquierdo-Garcia D, Ward N, Mangeat G, Granberg T, Klawiter EC, Catana C, Hooker JM, Taylor N, Ionete C, Kinkel RP, Mainero C.

Ann Neurol. 2016 Nov;80(5):776-790. doi: 10.1002/ana.24791. Epub 2016 Oct 25.

8.

Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.

Louapre C, Govindarajan ST, Giannì C, Langkammer C, Sloane JA, Kinkel RP, Mainero C.

Neurology. 2015 Nov 10;85(19):1702-9. doi: 10.1212/WNL.0000000000002106. Epub 2015 Oct 14.

9.

Is the Relationship between Cortical and White Matter Pathologic Changes in Multiple Sclerosis Spatially Specific? A Multimodal 7-T and 3-T MR Imaging Study with Surface and Tract-based Analysis.

Louapre C, Govindarajan ST, Giannì C, Cohen-Adad J, Gregory MD, Nielsen AS, Madigan N, Sloane JA, Kinkel RP, Mainero C.

Radiology. 2016 Feb;278(2):524-35. doi: 10.1148/radiol.2015150486. Epub 2015 Sep 2.

10.

No Evidence of Disease Activity in Multiple Sclerosis.

Sloane JA, Mainero C, Kinkel RP.

JAMA Neurol. 2015 Jul;72(7):835-6. doi: 10.1001/jamaneurol.2015.0587. No abstract available.

PMID:
26167901
11.

Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.

Kinkel RP, Simon JH, O'Connor P, Hyde R, Pace A.

Mult Scler Relat Disord. 2014 Nov;3(6):712-9. doi: 10.1016/j.msard.2014.08.003. Epub 2014 Aug 27.

PMID:
25891550
12.

Disease-related determinants of quality of life 10 years after clinically isolated syndrome.

Kinkel RP, Laforet G, You X.

Int J MS Care. 2015 Jan-Feb;17(1):26-34. doi: 10.7224/1537-2073.2013-041.

13.

A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.

Mainero C, Louapre C, Govindarajan ST, Giannì C, Nielsen AS, Cohen-Adad J, Sloane J, Kinkel RP.

Brain. 2015 Apr;138(Pt 4):932-45. doi: 10.1093/brain/awv011. Epub 2015 Feb 12.

14.

Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis.

Fan AP, Govindarajan ST, Kinkel RP, Madigan NK, Nielsen AS, Benner T, Tinelli E, Rosen BR, Adalsteinsson E, Mainero C.

J Cereb Blood Flow Metab. 2015 Jan;35(1):131-9. doi: 10.1038/jcbfm.2014.187. Epub 2014 Oct 29.

15.

Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.

Simon JH, Kinkel RP, Kollman C, O'Connor P, Fisher E, You X, Hyde R; CHAMPIONS Investigators Group.

Mult Scler. 2015 Apr;21(4):415-22. doi: 10.1177/1352458514547407. Epub 2014 Oct 24.

PMID:
25344370
16.

JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, Batson S, Koralnik IJ.

Ann Neurol. 2014 Jun;75(6):925-34. doi: 10.1002/ana.24148. Epub 2014 Jun 10.

17.

Association of multiple sclerosis susceptibility variants and early attack location in the CNS.

Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E.

PLoS One. 2013 Oct 10;8(10):e75565. doi: 10.1371/journal.pone.0075565. eCollection 2013.

18.

Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.

Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E.

PLoS One. 2013 Oct 9;8(10):e75416. doi: 10.1371/journal.pone.0075416. eCollection 2013.

19.

Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.

Nielsen AS, Kinkel RP, Madigan N, Tinelli E, Benner T, Mainero C.

Neurology. 2013 Aug 13;81(7):641-9. doi: 10.1212/WNL.0b013e3182a08ce8. Epub 2013 Jul 17.

20.

Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2.

Nielsen AS, Kinkel RP, Tinelli E, Benner T, Cohen-Adad J, Mainero C.

J Magn Reson Imaging. 2012 Mar;35(3):537-42. doi: 10.1002/jmri.22847. Epub 2011 Nov 1.

21.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators.

Arch Neurol. 2012 Feb;69(2):183-90. doi: 10.1001/archneurol.2011.1426. Epub 2011 Oct 10.

PMID:
21987393
22.

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.

Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP.

Mult Scler. 2012 Mar;18(3):377-8. doi: 10.1177/1352458511418631. Epub 2011 Aug 9. No abstract available.

PMID:
21828201
23.

Internet portal use in an academic multiple sclerosis center.

Nielsen AS, Halamka JD, Kinkel RP.

J Am Med Inform Assoc. 2012 Jan-Feb;19(1):128-33. doi: 10.1136/amiajnl-2011-000177. Epub 2011 May 12.

24.

In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.

Cohen-Adad J, Benner T, Greve D, Kinkel RP, Radding A, Fischl B, Rosen BR, Mainero C.

Neuroimage. 2011 Jul 1;57(1):55-62. doi: 10.1016/j.neuroimage.2011.04.009. Epub 2011 Apr 13.

25.

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.

Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE 3rd.

Mult Scler. 2011 Mar;17(3):353-60. doi: 10.1177/1352458510384605. Epub 2010 Oct 21.

PMID:
20965959
26.

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.

Miravalle A, Jensen R, Kinkel RP.

Arch Neurol. 2011 Feb;68(2):186-91. doi: 10.1001/archneurol.2010.257. Epub 2010 Oct 11.

PMID:
20937940
27.

Experiences acquiring and using mobility aids among working-age persons with multiple sclerosis living in communities in the United States.

Iezzoni LI, Rao SR, Kinkel RP.

Am J Phys Med Rehabil. 2010 Dec;89(12):1010-23. doi: 10.1097/PHM.0b013e3181f70292.

PMID:
20881588
28.

Discrepant findings in immune responses to JC virus in patients receiving natalizumab.

Tan CS, Chen Y, Viscidi RP, Kinkel RP, Stein MC, Koralnik IJ.

Lancet Neurol. 2010 Jun;9(6):565-6; author reply 566-7. doi: 10.1016/S1474-4422(10)70124-1. No abstract available.

29.

Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ.

N Engl J Med. 2009 Sep 10;361(11):1067-74. doi: 10.1056/NEJMoa0904267. Erratum in: N Engl J Med. 2011 May 12;364(19):1882.

30.

In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI.

Mainero C, Benner T, Radding A, van der Kouwe A, Jensen R, Rosen BR, Kinkel RP.

Neurology. 2009 Sep 22;73(12):941-8. doi: 10.1212/WNL.0b013e3181b64bf7. Epub 2009 Jul 29.

31.

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.

O'Connor P, Kinkel RP, Kremenchutzky M.

Mult Scler. 2009 Jun;15(6):728-34. doi: 10.1177/1352458509103173.

PMID:
19482863
32.

Patterns of mobility aid use among working-age persons with multiple sclerosis living in the community in the United States.

Iezzoni LI, Rao SR, Kinkel RP.

Disabil Health J. 2009 Apr;2(2):67-76. doi: 10.1016/j.dhjo.2008.12.001.

PMID:
21122745
33.

Acute paraplegia with vanishing white matter lesions.

Jensen RM, Kinkel RP.

Rev Neurol Dis. 2008 Summer;5(3):159-60; discussion 164-6.

PMID:
18838956
34.

Health-related quality of life assessment in multiple sclerosis.

Miller DM, Kinkel RP.

Rev Neurol Dis. 2008 Spring;5(2):56-64. Review.

PMID:
18660737
35.

Working-age persons with multiple sclerosis and access to disease-modifying medications.

Iezzoni LI, Ngo LH, Kinkel RP.

Mult Scler. 2008 Jan;14(1):112-22. Epub 2007 Sep 24.

PMID:
17893109
36.

Steroid-responsive neurologic relapses in a child with a proteolipid protein-1 mutation.

Gorman MP, Golomb MR, Walsh LE, Hobson GM, Garbern JY, Kinkel RP, Darras BT, Urion DK, Eksioglu YZ.

Neurology. 2007 Apr 17;68(16):1305-7.

PMID:
17438221
37.

Interferon-beta1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis.

Kinkel RP.

Expert Rev Clin Immunol. 2006 Sep;2(5):691-704. doi: 10.1586/1744666X.2.5.691.

PMID:
20477625
38.

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M; CHAMPIONS Study Group.

Neurology. 2006 Mar 14;66(5):678-84. Epub 2006 Jan 25.

PMID:
16436649
39.

Anti-tumor necrosis factor alpha-associated multiple sclerosis.

Titelbaum DS, Degenhardt A, Kinkel RP.

AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1548-50. Review.

40.

Acute ophthalmoplegia.

Brotman DJ, Taege A, Ruggieri P, Kinkel RP.

Lancet. 2003 Mar 15;361(9361):930. No abstract available.

PMID:
12648973
41.

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW.

Ann Neurol. 2002 Apr;51(4):481-90.

PMID:
11921054
42.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30. No abstract available.

PMID:
11902591
43.

Transcallosal bands: a sign of neuronal tract degeneration in early MS?

Simon JH, Jacobs L, Kinkel RP.

Neurology. 2001 Nov 27;57(10):1888-90.

PMID:
11723282
44.

Axonal loss in normal-appearing white matter in a patient with acute MS.

Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD.

Neurology. 2001 Oct 9;57(7):1248-52.

PMID:
11591844
45.

Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life.

Bethoux F, Miller DM, Kinkel RP.

Mult Scler. 2001 Apr;7(2):137-42.

PMID:
11424634
46.

Epitope spreading: a mechanism for progression of autoimmune disease.

Tuohy VK, Kinkel RP.

Arch Immunol Ther Exp (Warsz). 2000;48(5):347-51. Review.

PMID:
11140461
47.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW.

N Engl J Med. 2000 Sep 28;343(13):898-904.

48.

Traumatic intracerebral venous thrombosis associated with an abnormal golf swing.

Saneto RP, Samples S, Kinkel RP.

Headache. 2000 Jul-Aug;40(7):595-8. Review.

PMID:
10940100
49.

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.

Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd.

Neurology. 2000 Jul 25;55(2):185-92.

PMID:
10908888
50.

A Wallerian degeneration pattern in patients at risk for MS.

Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N.

Neurology. 2000 Mar 14;54(5):1155-60.

PMID:
10720290

Supplemental Content

Loading ...
Support Center